Clyra lands exclusive ViaCLYR distribution partner in MENA

By AI, Created 8:50 PM UTC, May 20, 2026, /AGP/ – Clyra Medical Technologies has signed an exclusive distribution agreement with Dubai-based Al-Hikma FZCO to commercialize ViaCLYR across the Middle East and North Africa, with room to expand into adjacent markets. The deal puts Clyra’s wound irrigation product in front of a broader regional network as regulatory work begins in key countries.

Why it matters: - The agreement gives Clyra Medical Technologies a dedicated channel to sell ViaCLYR across the Middle East and North Africa. - The deal could expand Clyra’s reach into adjacent markets if performance conditions are met. - The partnership may speed up access to a wound irrigation product built around Clyra’s proprietary copper-iodine technology.

What happened: - Clyra Medical Technologies announced an exclusive distribution agreement with Al-Hikma FZCO, headquartered in Dubai, United Arab Emirates. - The agreement covers commercialization of ViaCLYR across the Middle East and North Africa. - The companies said the arrangement also leaves room for expansion into adjacent markets. - Regulatory work needed for commercial sales has begun in key countries through a cooperative process between the two companies.

The details: - ViaCLYR is Clyra’s advanced wound irrigation solution. - The product uses Clyra’s proprietary Clyrasept Copper-Iodine Complex Solution technology. - Clyra describes the technology as a broad-spectrum antimicrobial designed to be effective, biocompatible and supportive of natural healing processes. - The agreement includes standard international distribution terms, including territory exclusivity tied to performance and customary cooperation and protections. - Steve Harrison, chief executive officer of Clyra Medical Technologies, said Al-Hikma is established, well connected across the region and credible with regulators and the clinical community. - Harrison also said Al-Hikma’s wound management portfolio makes ViaCLYR a natural fit and that regulatory work already underway positions the companies to build commercial momentum. - Dr. Ali Farooq Abdul-Qader, founder and group CEO of Al-Hikma FZCO, said Clyra’s copper-iodine technology aligns with Al-Hikma’s mission to bring innovative, high-quality healthcare products to the communities it serves. - Abdul-Qader said he expects a long and productive partnership. - Al-Hikma is a specialized healthcare distribution and marketing group founded in 2005. - The company exports to about 25 countries, has more than 50 local distributor partnerships and employs around 500 people. - Al-Hikma says it serves more than 500 million people across the Middle East, North Africa and adjacent regions. - Al-Hikma’s portfolio includes conventional pharmaceuticals, wound management, medical devices, generics, food supplements and over-the-counter products. - Clyra Medical Technologies is a subsidiary of BioLargo, Inc. and focuses on infection control and advanced wound care. - Clyra was founded in 2012 and develops wound care solutions based on its Copper-Iodine Complex Technology. - The company says it commercializes FDA-cleared products through strategic distribution partnerships. - More information is available on Clyra’s product page. - Additional company information is available at Al-Hikma’s website and Clyra’s website.

Between the lines: - The partnership pairs a regional distributor with broad market access and a wound-care focused product line. - Performance-based exclusivity suggests both companies are tying market access to execution, not just the signed contract. - Early regulatory activity matters because commercial sales in the region depend on country-by-country approvals.

What’s next: - Clyra and Al-Hikma will continue regulatory work in key countries across the territory. - Commercial sales should follow as approvals are secured and distribution plans move forward. - The companies may expand into adjacent markets if the partnership performs as expected. - Clyra’s broader strategy will likely lean on similar distribution partnerships to scale its wound care portfolio.